SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITY EXCHANGE ACT OF 1934
Date of report November 18, 1999
-----------------------------------------------------------------
NPS PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-23272 87-0439579
- ------------------------------------ ------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
420 Chipeta Way, Salt Lake City, Utah 84108-1256
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(801) 583-4939
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N/A
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On November 9, 1999, NPS Pharmaceuticals, Inc. announced that the
Canadian government agreed to make an investment in NPS's proposed merger
partner, Allelix Biopharmaceuticals Inc. The investment will support clinical
research and development of ALX-0600.
The press release is filed as an exhibit to this report and is
incorporated herein by reference.
The press release filed as an exhibit to this report includes "safe
harbor" language, pursuant to the Private Securities Litigation Reform Act of
1995, indicating that certain statements about NPS's business contained in the
press release is "forward-looking" rather than "historic."
Item 7. Financial Statements and Exhibits.
c. Exhibits
99.1 Press release, dated November 9, 1999, issued by NPS
Pharmaceuticals, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NPS PHARMACEUTICALS, INC.
Date: November 18, 1999 ______________________________
James U. Jensen, Vice President
2
INDEX TO EXHIBITS
Exhibit
- -------
Number Description
- ------ -----------
99.1 Press release, dated November 9, 1999, issued by NPS
Pharmaceuticals, Inc.
3